These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 25208876)
1. Laronidase-functionalized multiple-wall lipid-core nanocapsules: promising formulation for a more effective treatment of mucopolysaccharidosis type I. Mayer FQ; Adorne MD; Bender EA; de Carvalho TG; Dilda AC; Beck RC; Guterres SS; Giugliani R; Matte U; Pohlmann AR Pharm Res; 2015 Mar; 32(3):941-54. PubMed ID: 25208876 [TBL] [Abstract][Full Text] [Related]
2. Bromelain-Functionalized Multiple-Wall Lipid-Core Nanocapsules: Formulation, Chemical Structure and Antiproliferative Effect Against Human Breast Cancer Cells (MCF-7). Oliveira CP; Prado WA; Lavayen V; Büttenbender SL; Beckenkamp A; Martins BS; Lüdtke DS; Campo LF; Rodembusch FS; Buffon A; Pessoa A; Guterres SS; Pohlmann AR Pharm Res; 2017 Feb; 34(2):438-452. PubMed ID: 27981451 [TBL] [Abstract][Full Text] [Related]
3. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I. Jameson E; Jones S; Remmington T Cochrane Database Syst Rev; 2016 Apr; 4():CD009354. PubMed ID: 27033167 [TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I. Jameson E; Jones S; Wraith JE Cochrane Database Syst Rev; 2013 Nov; (11):CD009354. PubMed ID: 24257962 [TBL] [Abstract][Full Text] [Related]
5. Enzyme replacement therapy with laronidase (Aldurazyme) for treating mucopolysaccharidosis type I. Jameson E; Jones S; Wraith JE Cochrane Database Syst Rev; 2013 Sep; (9):CD009354. PubMed ID: 24085657 [TBL] [Abstract][Full Text] [Related]
6. Laronidase-loaded liposomes reach the brain and other hard-to-treat organs after noninvasive nasal administration. Schuh RS; Franceschi EP; Brum BB; Fachel FNS; Poletto É; Vera LNP; Santos HS; Medeiros-Neves B; Monteagudo de Barros V; Helena da Rosa Paz A; Baldo G; Matte U; Giugliani R; Ferreira Teixeira H Int J Pharm; 2024 Jul; 660():124355. PubMed ID: 38897489 [TBL] [Abstract][Full Text] [Related]
7. Docosahexaenoic acid nanoencapsulated with anti-PECAM-1 as co-therapy for atherosclerosis regression. de Castro Leão M; Raffin Pohlmann A; de Cristo Soares Alves A; Helena Poliselli Farsky S; Klimuk Uchiyama M; Araki K; Sandri S; Stanisçuaski Guterres S; Alves Castro I Eur J Pharm Biopharm; 2021 Feb; 159():99-107. PubMed ID: 33358940 [TBL] [Abstract][Full Text] [Related]
8. Plasma Pharmacokinetics of Valanafusp Alpha, a Human Insulin Receptor Antibody-Iduronidase Fusion Protein, in Patients with Mucopolysaccharidosis Type I. Pardridge WM; Boado RJ; Giugliani R; Schmidt M BioDrugs; 2018 Apr; 32(2):169-176. PubMed ID: 29442294 [TBL] [Abstract][Full Text] [Related]
10. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Wraith JE; Beck M; Lane R; van der Ploeg A; Shapiro E; Xue Y; Kakkis ED; Guffon N Pediatrics; 2007 Jul; 120(1):e37-46. PubMed ID: 17606547 [TBL] [Abstract][Full Text] [Related]
12. Transcranial pulsed ultrasound facilitates brain uptake of laronidase in enzyme replacement therapy for Mucopolysaccharidosis type I disease. Hsu YH; Liu RS; Lin WL; Yuh YS; Lin SP; Wong TT Orphanet J Rare Dis; 2017 Jun; 12(1):109. PubMed ID: 28595620 [TBL] [Abstract][Full Text] [Related]
13. Biodistribution and pharmacodynamics of recombinant human alpha-L-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected cats following multiple intrathecal administrations. Vite CH; Wang P; Patel RT; Walton RM; Walkley SU; Sellers RS; Ellinwood NM; Cheng AS; White JT; O'Neill CA; Haskins M Mol Genet Metab; 2011 Jul; 103(3):268-74. PubMed ID: 21482164 [TBL] [Abstract][Full Text] [Related]
14. Carbon nanotubes as nanovectors for intracellular delivery of laronidase in Mucopolysaccharidosis type I. Da Ros T; Ostric A; Andreola F; Filocamo M; Pietrogrande M; Corsolini F; Stroppiano M; Bruni S; Serafino A; Fiorito S Nanoscale; 2018 Jan; 10(2):657-665. PubMed ID: 29239447 [TBL] [Abstract][Full Text] [Related]
15. Ocular lesions in canine mucopolysaccharidosis I and response to enzyme replacement therapy. Newkirk KM; Atkins RM; Dickson PI; Rohrbach BW; McEntee MF Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5130-5. PubMed ID: 21436264 [TBL] [Abstract][Full Text] [Related]
16. Characterization and downstream mannose phosphorylation of human recombinant α-L-iduronidase produced in Arabidopsis complex glycan-deficient (cgl) seeds. He X; Pierce O; Haselhorst T; von Itzstein M; Kolarich D; Packer NH; Gloster TM; Vocadlo DJ; Qian Y; Brooks D; Kermode AR Plant Biotechnol J; 2013 Dec; 11(9):1034-43. PubMed ID: 23898885 [TBL] [Abstract][Full Text] [Related]
17. Uptake of a recombinant human alpha-L-iduronidase (laronidase) by cultured fibroblasts and osteoblasts. Tsukimura T; Tajima Y; Kawashima I; Fukushige T; Kanzaki T; Kanekura T; Ikekita M; Sugawara K; Suzuki T; Togawa T; Sakuraba H Biol Pharm Bull; 2008 Sep; 31(9):1691-5. PubMed ID: 18758061 [TBL] [Abstract][Full Text] [Related]
18. Anthropometric data of 14 patients with mucopolysaccharidosis I: retrospective analysis and efficacy of recombinant human alpha-L-iduronidase (laronidase). Tylki-Szymanska A; Rozdzynska A; Jurecka A; Marucha J; Czartoryska B Mol Genet Metab; 2010 Jan; 99(1):10-7. PubMed ID: 19783188 [TBL] [Abstract][Full Text] [Related]
19. Alternative laronidase dose regimen for patients with mucopolysaccharidosis I: a multinational, retrospective, chart review case series. Horovitz DD; Acosta AX; Giugliani R; Hlavatá A; Hlavatá K; Tchan MC; Lopes Barth A; Cardoso L; Embiruçu de Araújo Leão EK; Esposito AC; Kyosen SO; De Souza CF; Martins AM Orphanet J Rare Dis; 2016 Apr; 11(1):51. PubMed ID: 27129473 [TBL] [Abstract][Full Text] [Related]